Indian Journal of Medical Research

REVIEW ARTICLE
Year
: 2018  |  Volume : 148  |  Issue : 2  |  Page : 135--144

New genetic players in late-onset Alzheimer's disease: Findings of genome-wide association studies


Anamika Misra, Sankha Shubhra Chakrabarti, Indrajeet Singh Gambhir 
 Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India

Correspondence Address:
Dr Indrajeet Singh Gambhir
Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi 221 005, Uttar Pradesh
India

Abstract

Late-onset Alzheimer's disease (LOAD) or sporadic AD is the most common form of AD. The precise pathogenetic changes that trigger the development of AD remain largely unknown. Large-scale genome-wide association studies (GWASs) have identified single-nucleotide polymorphisms in multiple genes which are associated with AD; most notably, these are ABCA7, bridging integrator 1 (B1N1), triggering receptor expressed on myeloid cells 2 (TREM2), CD33, clusterin (CLU), complement receptor 1 (CRI), ephrin type-A receptor 1 (EPHA1), membrane-spanning 4-domains, subfamily A (MS4A) and phosphatidylinositol binding clathrin assembly protein (PICALM) genes. The proteins coded by the candidate genes participate in a variety of cellular processes such as oxidative balance, protein metabolism, cholesterol metabolism and synaptic function. This review summarizes the major gene loci affecting LOAD identified by large GWASs. Tentative mechanisms have also been elaborated in various studies by which the proteins coded by these genes may exert a role in AD pathogenesis have also been elaborated. The review suggests that these may together affect LOAD pathogenesis in a complementary fashion.



How to cite this article:
Misra A, Chakrabarti SS, Gambhir IS. New genetic players in late-onset Alzheimer's disease: Findings of genome-wide association studies.Indian J Med Res 2018;148:135-144


How to cite this URL:
Misra A, Chakrabarti SS, Gambhir IS. New genetic players in late-onset Alzheimer's disease: Findings of genome-wide association studies. Indian J Med Res [serial online] 2018 [cited 2019 Aug 24 ];148:135-144
Available from: http://www.ijmr.org.in/text.asp?2018/148/2/135/243685


Full Text

 Introduction



The first case of Alzheimer's disease (AD) was described more than 100 years ago, but the precise pathogenetic changes leading to the development of AD are still a matter of considerable controversy. Based on the age of onset and heredity, AD is classified into early-onset AD (EOAD), late-onset AD (LOAD) and familial AD. LOAD or sporadic AD is the most common form of AD, accounting for about 90 per cent of cases and usually occurring after the age of 65 yr [1]. Neurofibrillary tangles of phosphorylated tau protein and senile plaques composed of amyloid β (Aβ)-protein are the two characteristic pathological hallmarks of AD; however, there exists controversy in how well these correlate with AD phenotype as some AD brains on post-mortem examination reveal minimal plaques and tangles [2].

The protein apolipoprotein E (ApoE) is the only well-established genetic risk factor for LOAD. The APOE gene consists of four exons and three introns, with a total of 3597 base pairs, and is mapped to chromosome 19. ApoE is polymorphic with three major isoforms, ApoE2, ApoE3 and ApoE4. High frequency of the APOE4 allele is found in patients with AD than in the general population [3]. ApoE4 is known to inhibit neurite outgrowth, disrupt neuronal cytoskeleton [4], stimulate tau phosphorylation and cause neurodegeneration [5]. However, neither is the APOE4 variant present in all AD cases nor is it absolutely essential for AD pathogenesis [6]. Multiple rare mutations in the amyloid precursor protein gene (APP), PSEN1 gene and PSEN2 gene cause early-onset AD [7]. However, a large case-control study (3940 cases and 13,373 controls) reported that common variants in these genes were not likely to make strong contributions to susceptibility for LOAD [8].

Recent efforts have been focussed on conducting genome-wide association studies (GWASs) to identify newer risk genes for LOAD. Multi-stage meta-analytic reports by different groups documented the association of single-nucleotide polymorphisms (SNPs) in 10 genes with AD; these being ABCA7, bridging integrator 1 gene (BIN1), triggering receptor expressed on myeloid cells gene (TREM), CD33, clusterin gene (CLU), complement receptor 1 gene (CR1), ephrin type-A receptor 1 gene (EPHA1), CD2AP, membrane-spanning 4-domains, subfamily A (MS4A) gene cluster and phosphatidylinositol binding clathrin assembly protein gene (PICALM)[9],[10],[11],[12].

In 2009, Lambert et al[13] published an open letter of two-stage GWAS performed on AD subjects and controls. The three-city study identified two new susceptibility loci: CLU and CR1. They also detected evidence for the association of PICALM with AD [13]. A collaborative consortium from Europe and the USA [European AD Initiative 1 (EADI 1)] also performed a GWAS over 16,000 individuals with AD and controls. They identified two novel loci CLU and PICALM, significantly associated with AD. They also observed one more associated locus BIN1[14]. In 2010, Seshadri et al[15] performed a three-stage analysis of GWAS data to identify additional loci associated with LOAD. In their gene discovery phase, they concluded that BIN1 showed association with AD in GWAS. They also confirmed the association of two reported loci; CLU and PICALM with LOAD [15]. Hollingworth et al[10] undertook a combined analysis of four independent genome-wide studies- GERAD1, TGEN1, ADNI and EADI1 - to identify new susceptibility loci of AD. Their data provided significant evidence for the association of ABCA7, MS4A gene cluster with AD at stage one. In stage two, they observed association of more suggestive loci; CD33 and EPHA1 with AD [10]. To identify newer susceptibility loci for AD, the AD Genetic Consortium (ADGC) group conducted a three-staged association study on AD patients and provided compelling evidence for the association of MS4A4A, EPHA1 and CD33 with AD. They also replicated previous associations of CR1, CLU and PICALM with LOAD [11]. Advances in sequencing techniques of entire genomes identified rare variants in those patients, in whom linkage analysis cannot be done. TREM2 is one of the variants that increase the risk of AD [12].

[Figure 1] gives a schematic representation of the multiple research groups who worked to find new susceptibility genes for LOAD and also the different loci which affect LOAD pathogenesis.{Figure 1}

Alzheimer's disease (AD) pathogenesis as the cumulative effect of multiple genetic risk factors

Large-scale GWASs have identified SNPs in ten genes: ABCA7, BIN1, TREM2, CD33, CLU, CR1, EPHA1, MS4A, CD2AP and PICALM which may participate in the pathogenesis of AD by several functional pathways that are affected [9],[10],[11],[12]. These genes may be categorized on the bases of their involvement in cellular pathways:

(i) Immune response and inflammation: CR1, MS4A family, EPHA1, CD33, TREM[9],[10],[12].

(ii) Lipid (cholesterol) metabolism: CLU and ABCA7[9],[10].

(iii) Endocytosis and synaptic function: PICALM, BIN1, CD2AP and EPHA1[9],[10].

It is hypothesized that these gene SNPs identified by GWAS influence their respective interconnected cellular processes to cause AD. The exact pathogenesis of AD is still unclear, and it is possible that not all of the above processes are deranged in each case of LOAD. Either of the three may dominate in or solely contribute to LOAD in individual patients. Further, the exact links between the pathways still need to be worked out. However, the common pathways through which these act are widely believed to be the amyloidogenic pathway and the tau hyper-phosphorylation pathway [1].

[Figure 2] represents how the various genetic risk factors may be interconnected and contribute to LOAD risk by ultimately inducing amyloid and hyper-phosphorylated tau protein accumulation.{Figure 2}

Functional significance of new genetic loci associated with LOAD

Genes associated with lipid metabolism: CLU codes for the secretory hetero-dimeric 75-80 kDa CLU also known as apolipoprotein J [16]. This gene encodes a 2 kb mRNA which translates into a 449 amino acid primary polypeptide chain [17]. CLU is a highly conserved chaperone protein that is found in the cell cytosol under some stress conditions [18]. It is expressed in most mammalian tissues [19], and has been reported to be involved in neurodegeneration and hypoxic-ischaemic neuronal death [20]. Elevated level of CLU has been found in post-mortem AD brains and also in the brains of ApoE4 carriers [21]. CLU is involved in the regulation of Aβ. This has been demonstrated in guinea pig brain perfusion model where apolipoprotein J interacts with the soluble form of Aβ in a specific and reversible manner and forms complexes in the brain, facilitating the transport of soluble Aβ across the blood-brain barrier [22]. In transgenic mouse model (clu − and clu +), it has been seen that Aβ deposits in clu − mice are significantly reduced as compared to clu + which indicates that CLU has a role in Aβ fibril formation and neurotoxicity [23]. Plasma CLU level was reported to be associated with rapid clinical progression in AD, suggesting its possible use as a biomarker of AD [24]. GWASs found a significant negative association [odds ratio (OR)=0.86] between an SNP within the CLU, rs11136000 and the risk of having AD [14]. This association was found in both APOE4 carriers and non-carriers [15].

ABCA7 is a member of the superfamily of ATP-binding cassette (ABC) transporters, which transport various molecules across extra- and intra-cellular membranes. These transporters are divided into eight distinct subfamilies. ABCA7 is a member of the ABC1 subfamily [25]. This gene codes for a membrane protein which is expressed in the myelolymphatic tissues, brain and trachea [26]. Analysis of isolated foetal human brain cells has shown that microglia express the highest level of ABCA7 mRNA [27]. This gene is also involved in AD pathogenesis [28]. It regulates the phagocytosis of apoptotic cell debris inside the brain. Protein products of these loci bind with APOA1 and contribute to the apolipoprotein-mediated phospholipid efflux mechanism in cells [29].

In stage 1 meta-analysis of GERAD1, TGEN1, ADNI and EADI1, evidence was found for the positive association (OR=1.22) of SNP of ABCA7 (rs3764650) with AD. This has further been proven in stages 2 and 3 meta-analysis [10]. Another SNP variant of ABCA7, i.e. rs3752246, was found to be associated with AD in stage 2 meta-analysis (OR=1.17). However, association of rs3764650 with ABCA7 expression was not observed [30].

Genes associated with inflammatory response: CD33 is located on chromosome 19q13.3 in humans and codes for the 67kDa CD33 protein [31]. CD33 belongs to the sialic acid-binding immunoglobulin-like lectins (Siglecs) family [32]. It is expressed in microglial cells in the human brain [33]. The Siglecs family mediates cell-cell interaction through glycan recognition [34]. They also play an important role in the regulation of functions of innate and adaptive immune cell systems [35]. CD33 is expressed by haematopoietic and phagocytic cells and participates in adhesion processes of human primary immune cells [36]. It appears to inhibit the production of pro-inflammatory cytokines [such as interleukin-1β, tumour necrosis factor alpha (TNF-α)] by monocytes [37]. Being an inhibitory receptor in immune response, it also regulates cell growth and survival and also induces apoptosis [38].

CD33 inhibits Aβ clearance in LOAD [39]. It has been seen that levels of CD33-positive microglial cells are increased in brains of AD patients, and play a direct role in the progression of AD. The CD33 SNP rs3865444, which confers protection against AD, has been seen to be associated with reductions in both CD33 expression and insoluble Aβ42 levels in AD brain [33]. Various SNPs of CD33 such as rs3826656 and rs3865444 are found to be associated with AD [40].

CR1 found on chromosome 1q32 codes for the complement regulatory protein, CR1 or CD35 which is expressed widely on a number of blood cells [41] and can also be found dissolved in the blood plasma [42]. CR1 induces phagocytosis by forming a complex with C3b/C4b. Extracellular domain of CR1 is composed of long homologous repeats (LHRs). Genetic duplications and deletions result in increased number of LHR regions, which result in the formation of four co-dominant alleles of CR1. Frequencies of the four alleles vary only slightly between populations [43]. The increased number of LHRs means that the larger alleles have additional C3b/C4b-binding sites [44].

The classical complement pathway has been long known to play a protective role in AD by acceleration of clearance of the Aβ plaques. Aβ interacts with C1q of the classical complement pathway [45]. This results in the activation of the membrane attack complex comprising C3b/C4b, which results in activation of glial cells [46]. CR1 helps in this process by providing multiple C3b/C4b-binding sites [47]. Lambert et al[13] found an SNP variant of CR1, rs6656401 (OR=1.12) with a strong association with LOAD.

EPHA1 also known as eph is located on chromosome 7q34.1. The protein product belongs to the tyrosine kinase receptor family [48] and the ephrin receptor subfamily. The ligand for the EphA receptor is ephrin-A, which is anchored to the cell membrane through a glycosylphosphatidylinositol linkage [49]. Eph receptors and ephrins are expressed in endothelial and epithelial cells [50], and guide the migration of cells during embryonic development and also have a role in cytoskeletal organization of neuronal processes [51]. They play a role in synaptic development and plasticity [52]. Additional roles in apoptosis and inflammation exist [53]. AD patients with an allele of EPHA1 (A allele) having enhanced rate of cerebral metabolism for glucose in the right lateral occipitotemporal gyrus and inferior temporal gyrus may not have hippocampal atrophy [54]. Combined result of the meta-analysis of the GERAD consortia with the ADGC GWAS shows that the rs11767557 SNP of the EPHA1 gene is negatively associated with AD (OR=0.90)[10].

MS4A encodes several proteins including CD20. This gene family is further divided into at least 12 subgroups from MS4A1 to MS4A12[55]. CD20 expressed by B-lymphocytes [56] forms a hetero-tetrameric complex on the cell membrane that regulates Ca 2+ influx downstream [57]. This regulation of calcium signalling may have an important role in neurodegeneration and AD pathogenesis [58]. Several members of this cluster (such as MS4A1, MS4A2 and MS4A4B) have an important role in immunity [59]. MS4A4B appears to have a role in Th1 development, CD8+ memory T-cell function and modulation of regulatory T-cell signalling [60]. MS4A2 mediates interactions with IgE-bound antigens that lead to cellular responses such as the degranulation of mast cells [61].

Meta-analysis data of GWAS by ADGC suggested two SNPs of the MS4A gene cluster: rs610932 and rs670139 to be associated with LOAD [10]. Another independent GWAS study on the Spanish population revealed the association of rs1562990 SNP of MS4A with AD [62].

TREM2 codes for a membrane glycoprotein, consisting of an extracellular immunoglobulin-like domain and a cytoplasmic tail that is involved in receptor signalling complex along with the DAP12 and TYRO binding proteins [63]. This protein functions in the immune response and may be involved in chronic inflammation [64]. In brain cells, TREM2 is primarily expressed on microglia [65],[66]. Microglia stimulate the proliferation of CD4+ T-cells, as well as the secretion of TNF and CCL2[67]. Microglia have phagocytic role on amyloid plaques [68]. In a study, reduced phagocytic activity was found in microglial cells to phagocytose β amyloid fragment of AD brain in TREM2 knockdown mice in comparison with mice expressing TREM2[69]. A rare missense mutation (rs75932628) in the TREM2 results in an R47H substitution which has been found to confer a significant risk of AD. This may be because of the inability of the brain to clear Aβ toxicity [65].

Genes associated with endocytosis: PICALM codes for PICALM which can influence the risk of AD through modulation of APP processing via AP2-dependent clathrin-mediated endocytotic pathways, resulting in changes in Aβ level [70]. PICALM initiates clathrin polymerization at sites of coated pit formation [71]. It was seen in cell culture experiments that clathrin-mediated endocytosis (CME) retrieved full length APP from the cell surface, thus promoting the intracellular accumulation of amyloid [72]. In the endosome, full length APP is cleaved in to Aβ by β-secretase (BACE) and this is released into the brain interstitial fluid. Increased number of endosomes formed by CME drives more APP into the cell [73], resulting in an increase of Aβ production [74]. Synaptic vesicles limit the dispersion of neurotransmitter at the pre-synaptic plasma membrane. It was seen in live cell image of hippocampal neurons that synaptic vesicle containing VAMP2 on surface helped in diffusing neurotransmitters along the axonal membrane [75]. PICALM may also be involved in directing the trafficking of VAMP2[76]. The SNP of PICALM which has been found to be most significantly protective against LOAD is rs3851179 (OR=0.86)[14].

BIN1 codes for Myc box-dependent-interacting protein 1. It is a nucleo-cytoplasmic tumour suppressor adaptor protein [77]. Isoforms of this protein expressed in the central nervous system are involved in synaptic vesicle endocytosis [78]. The BIN1 is identified as the most important genetic susceptibility locus in LOAD after APOE[79]. Higher BIN1 expression has been reported to be linked with later age at onset and shorter disease duration [80]. Although the mechanisms are still not fully understood, data suggest that BIN1 affects AD risk primarily by modulating tau pathology. BIN1 also affects other cellular functions including endocytosis/trafficking, inflammation, calcium homoeostasis and apoptosis [79]. Seshadri et al[15] combined the data from CHARGE, TGEN, EADI1 and GERAD1 groups and analyzed by a three-stage sequential meta-analysis. They reported the association (OR=1.13) of the BIN1 SNP rs744373 with LOAD [15]. Another independent study- The Washington Heights-Inwood Columbia Aging Project and the Estudio Familiar de Influencia Genetica de Alzheimer study also showed positive associations of the BIN1 SNP rs7561528 with LOAD in the ε4 carrier state [81].

CD2AP codes for CD2-associated protein which is a scaffolding molecule that regulates the actin cytoskeleton [82]. It plays a role in receptor-mediated endocytosis. CD2AP contributes to APP metabolism and subsequent Aβ generation [83]. It regulates the encounter of APP and BACE1 in axonal and dendritic endosomes [84]. GERAD1, EADI1, deCODE and AD-IG GWAS datasets observed independent evidence for the association of CD2AP gene loci with AD (OR=1.11 for rs9349407 SNP)[10].

Racial variation of Alzheimer's disease susceptibility genes

Survival after the diagnosis of AD varies amongst different races, ranging from 3 to 9 years. African American and Latino AD patients have better survival than Caucasian patients and genetic background plays an important role in the progression of AD [85]. Most GWASs and replication studies of AD have been done in populations of European descent, and non-European genetic studies of new AD-susceptibility loci are limited. Studies that evaluated the association of CLU and CR1 with AD in Asian populations are limited [86]. Many AD-associated SNPs of CLU, PICALM and BIN1 were not necessarily identical in Caribbean Hispanic individuals compared with a European American data set [81]. Meta-analytic data showed that CLU, PICALM and CR1 were associated with LOAD in Caucasians subjects, but a study found that investigated SNPs of CR1, CLU and PICALM were not associated with AD in a Polish population [87]. A study found that in the Korean population, the PICALM is the only AD susceptibility loci in addition to APOE[88]. ADGC assembled multiple data sets for meta-analysis representing African American older subjects. The data showed another SNP (rs115550680) of ABCA7 (OR=1.79) was associated with AD in comparison to European ancestry [89].

Potential therapeutic implications of GWAS loci

Novel loci may exert their effects in a number of pathways such as oxidative balance, protein metabolism, cholesterol metabolism and synaptic function [90]. Genes with moderate to large effects on LOAD risk are valuable targets for therapeutic development. Neuroinflammation is both a cause and a consequence of AD and treatment with anti-inflammatory agents is likely to be successful if initiated before the onset of neurological symptoms [91]. Similarly, on the lipid metabolism front, the CLU protein may be targeted to reduce AD risk [92]. Genes associated with endocytosis and synaptic functions are BIN1, PICALM and CD2AP. Modulating these at the gene-expression level using siRNA or antisense techniques is a valid approach.

New developments

While the present review focuses on the most established gene loci involved in AD pathogenesis as suggested by GWAS, several newer loci have made a foray into the AD scene. Under the supervision and support of International Genomics of AD project, two-stage meta-analysis identified 11 loci which are HLA-DRB5-DRB1 gene, SORL1, PTK2B, SLC24A4, ZCWPW1, INPP5D, MEF2C, CELF1, NME8, CASS4, FERMT2 genes, with suggestive evidence of association with AD [93]. The [Table 1] represents newer loci involved in AD pathogenesis as suggested by GWAS with tentative pathogenic mechanisms [94].{Table 1}

 Conclusion



GWASs have revealed the association of new gene loci with AD. The first few identified SNPs from GWAS suggest the involvement of different associated pathways with pathogenesis of AD although the exact mechanisms remain unknown. Modification and advancing the research in these pathways may lead to therapeutic intervention for AD. Many of these GWAS loci may serve as biomarkers of AD. The search for additional genetic risk factors requires more large-scale meta-analysis of GWAS and enhanced statistical power as well as replicating these findings at the molecular level. Exciting times await us in AD genetic research and newer paradigms might open in the near future.

Financial support & sponsorship: None.

Conflicts of interest: None.

References

1Bekris LM, Yu CE, Bird TD, Tsuang DW. Genetics of Alzheimer disease. J Geriatr Psychiatry Neurol 2010; 23 : 213-27.
2Tiraboschi P, Hansen LA, Thal LJ, Corey-Bloom J. The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology 2004; 62 : 1984-9.
3Ward A, Crean S, Mercaldi CJ, Collins JM, Boyd D, Cook MN, et al. Prevalence of apolipoprotein E4 genotype and homozygotes (APOE e4/4) among patients diagnosed with Alzheimer's disease: A systematic review and meta-analysis. Neuroepidemiology 2012; 38 : 1-7.
4Nathan BP, Bellosta S, Sanan DA, Weisgraber KH, Mahley RW, Pitas RE, et al. Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science 1994; 264 : 850-2.
5Li G, Bien-Ly N, Andrews-Zwilling Y, Xu Q, Bernardo A, Ring K, et al. GABAergic interneuron dysfunction impairs hippocampal neurogenesis in adult apolipoprotein E4 knockin mice. Cell Stem Cell 2009; 5 : 634-45.
6Grupe A, Abraham R, Li Y, Rowland C, Hollingworth P, Morgan A, et al. Evidence for novel susceptibility genes for late-onset Alzheimer's disease from a genome-wide association study of putative functional variants. Hum MolGenet 2007; 16 : 865-73.
7Cruchaga C, Haller G, Chakraverty S, Mayo K, Vallania FL, Mitra RD, et al. Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer's disease families. PLoS One 2012; 7 : e31039.
8Gerrish A, Russo G, Richards A, Moskvina V, Ivanov D, Harold D, et al. The role of variation at aβPP, PSEN1, PSEN2, and MAPT in late onset Alzheimer's disease. J Alzheimers Dis 2012; 28 : 377-87.
9Jun G, Naj AC, Beecham GW, Wang LS, Buros J, Gallins PJ, et al. Meta-analysis confirms CR1, CLU, and PICALM as Alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch Neurol 2010; 67 : 1473-84.
10Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet 2011; 43 : 429-35.
11Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet 2011; 43 : 436-41.
12Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, et al.TREM2 variants in Alzheimer's disease. N Engl J Med 2013; 368 : 117-27.
13Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 2009; 41 : 1094-9.
14Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009; 41 : 1088-93.
15Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, Boada M, et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 2010; 303 : 1832-40.
16Yu JT, Tan L. The role of clusterin in Alzheimer's disease: Pathways, pathogenesis, and therapy. Mol Neurobiol 2012; 45 : 314-26.
17Park S, Mathis KW, Lee IK. The physiological roles of apolipoprotein J/clusterin in metabolic and cardiovascular diseases. Rev Endocr Metab Disord 2014; 15 : 45-53.
18Trougakos IP. The molecular chaperone apolipoprotein J/clusterin as a sensor of oxidative stress: Implications in therapeutic approaches - A mini-review. Gerontology 2013; 59 : 514-23.
19Alon U, Barkai N, Notterman DA, Gish K, Ybarra S, Mack D, et al. Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays. Proc Natl Acad Sci U S A 1999; 96 : 6745-50.
20Jones SE, Jomary C. Clusterin. Int J Biochem Cell Biol 2002; 34 : 427-31.
21Lidström AM, Bogdanovic N, Hesse C, Volkman I, Davidsson P, Blennow K, et al. Clusterin (apolipoprotein J) protein levels are increased in hippocampus and in frontal cortex in Alzheimer's disease. Exp Neurol 1998; 154 : 511-21.
22Zlokovic BV, Martel CL, Matsubara E, McComb JG, Zheng G, McCluskey RT, et al. Glycoprotein 330/megalin: Probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers. Proc Natl Acad Sci U S A 1996; 93 : 4229-34.
23DeMattos RB, O'dell MA, Parsadanian M, Taylor JW, Harmony JA, Bales KR, et al. Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 2002; 99 : 10843-8.
24Thambisetty M, Simmons A, Velayudhan L, Hye A, Campbell J, Zhang Y, et al. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry 2010; 67 : 739-48.
25Klein I, Sarkadi B, Váradi A. An inventory of the human ABC proteins. Biochim Biophys Acta 1999; 1461 : 237-62.
26Chan SL, Kim WS, Kwok JB, Hill AF, Cappai R, Rye KA, et al. ATP-binding cassette transporter A7 regulates processing of amyloid precursor protein in vitro. J Neurochem 2008; 106 : 793-804.
27Kim WS, Guillemin GJ, Glaros EN, Lim CK, Garner B. Quantitation of ATP-binding cassette subfamily - A transporter gene expression in primary human brain cells. Neuroreport 2006; 17 : 891-6.
28Karch CM, Goate AM. Alzheimer's disease risk genes and mechanisms of disease pathogenesis. Biol Psychiatry 2015; 77 : 43-51.
29Ikeda Y, Abe-Dohmae S, Munehira Y, Aoki R, Kawamoto S, Furuya A, et al. Posttranscriptional regulation of human ABCA7 and its function for the apoA-I-dependent lipid release. Biochem Biophys Res Commun 2003; 311 : 313-8.
30Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nat Methods 2010; 7 : 248-9.
31Barber RC. The genetics of Alzheimer's disease. Scientifica (Cairo) 2012; 2012 : 246210.
32Varki A, Crocker PR. I-type lectins. J Biol Chem 1995; 270 : 14243-6.
33Griciuc A, Serrano-Pozo A, Parrado AR, Lesinski AN, Asselin CN, Mullin K, et al. Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron 2013; 78 : 631-43.
34Macauley MS, Crocker PR, Paulson JC. Siglec-mediated regulation of immune cell function in disease. Nat Rev Immunol 2014; 14 : 653-66.
35Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. Nat Rev Immunol 2007; 7 : 255-66.
36Jandus C, Simon HU, von Gunten S. Targeting siglecs - a novel pharmacological strategy for immuno- and glycotherapy. Biochem Pharmacol 2011; 82 : 323-32.
37Gonzalez Y, Herrera MT, Soldevila G, Garcia-Garcia L, Fabián G, Pérez-Armendariz EM, et al. High glucose concentrations induce TNF-α production through the down-regulation of CD33 in primary human monocytes. BMC Immunol 2012; 13 : 19.
38Vitale C, Romagnani C, Falco M, Ponte M, Vitale M, Moretta A, et al. Engagement of p75/AIRM1 or CD33 inhibits the proliferation of normal or leukemic myeloid cells. Proc Natl Acad Sci U S A 1999; 96 : 15091-6.
39Gandy S, Heppner FL. Microglia as dynamic and essential components of the amyloid hypothesis. Neuron 2013; 78 : 575-7.
40Bertram L, Lange C, Mullin K, Parkinson M, Hsiao M, Hogan MF, et al. Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. Am J Hum Genet 2008; 83 : 623-32.
41Liu D, Niu ZX. The structure, genetic polymorphisms, expression and biological functions of complement receptor type 1 (CR1/CD35). Immunopharmacol Immunotoxicol 2009; 31 : 524-35.
42Krych-Goldberg M, Moulds JM, Atkinson JP. Human complement receptor type 1 (CR1) binds to a major malarial adhesin. Trends Mol Med 2002; 8 : 531-7.
43Wong WW, Wilson JG, Fearon DT. Genetic regulation of a structural polymorphism of human C3b receptor. J Clin Invest 1983; 72 : 685-93.
44Brouwers N, Van Cauwenberghe C, Engelborghs S, Lambert JC, Bettens K, Le Bastard N, et al. Alzheimer risk associated with a copy number variation in the complement receptor 1 increasing C3b/C4b binding sites. Mol Psychiatry 2012; 17 : 223-33.
45Nayak A, Ferluga J, Tsolaki AG, Kishore U. The non-classical functions of the classical complement pathway recognition subcomponent C1q. Immunol Lett 2010; 131 : 139-50.
46Bradt BM, Kolb WP, Cooper NR. Complement-dependent proinflammatory properties of the Alzheimer's disease beta-peptide. J Exp Med 1998; 188 : 431-8.
47Furtado PB, Huang CY, Ihyembe D, Hammond RA, Marsh HC, Perkins SJ, et al. The partly folded back solution structure arrangement of the 30 SCR domains in human complement receptor type 1 (CR1) permits access to its C3b and C4b ligands. J Mol Biol 2008; 375 : 102-18.
48Kuang SQ, Bai H, Fang ZH, Lopez G, Yang H, Tong W, et al. Aberrant DNA methylation and epigenetic inactivation of eph receptor tyrosine kinases and ephrin ligands in acute lymphoblastic leukemia. Blood 2010; 115 : 2412-9.
49Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002; 298 : 1912-34.
50Yamazaki T, Masuda J, Omori T, Usui R, Akiyama H, Maru Y, et al. EphA1 interacts with integrin-linked kinase and regulates cell morphology and motility. J Cell Sci 2009; 122 : 243-55.
51Wilkinson DG. Multiple roles of EPH receptors and ephrins in neural development. Nat Rev Neurosci 2001; 2 : 155-64.
52Pitulescu ME, Adams RH. Eph/ephrin molecules - A hub for signaling and endocytosis. Genes Dev 2010; 24 : 2480-92.
53Wang WY, Tan MS, Yu JT, Tan L. Role of pro-inflammatory cytokines released from microglia in Alzheimer's disease. Ann Transl Med 2015; 3 : 136.
54Wang HF, Tan L, Hao XK, Jiang T, Tan MS, Liu Y, et al. Effect of EPHA1 genetic variation on cerebrospinal fluid and neuroimaging biomarkers in healthy, mild cognitive impairment and Alzheimer's disease cohorts. J Alzheimers Dis 2015; 44 : 115-23.
55Liang Y, Buckley TR, Tu L, Langdon SD, Tedder TF. Structural organization of the human MS4A gene cluster on chromosome 11q12. Immunogenetics 2001; 53 : 357-68.
56Kuijpers TW, Bende RJ, Baars PA, Grummels A, Derks IA, Dolman KM, et al. CD20 deficiency in humans results in impaired T cell-independent antibody responses. J Clin Invest 2010; 120 : 214-22.
57Fengling M, Qingxiang G, Lijia Z, Wei Z. Influx of extracellular calcium participates in rituximab-enhanced ionizing radiation-induced apoptosis in Raji cells. Toxicol Lett 2012; 209 : 221-6.
58Mattson MP. Calcium and neurodegeneration. Aging Cell 2007; 6 : 337-50.
59Ma J, Yu JT, Tan L. MS4A cluster in Alzheimer's disease. Mol Neurobiol 2015; 51 : 1240-8.
60Xu H, Yan Y, Williams MS, Carey GB, Yang J, Li H, et al. MS4a4B, a CD20 homologue in T cells, inhibits T cell propagation by modulation of cell cycle. PLoS One 2010; 5 : e13780.
61Howie D, Nolan KF, Daley S, Butterfield E, Adams E, Garcia-Rueda H, et al. MS4A4B is a GITR-associated membrane adapter, expressed by regulatory T cells, which modulates T cell activation. J Immunol 2009; 183 : 4197-204.
62Antúnez C, Boada M, González-Pérez A, Gayán J, Ramírez-Lorca R, Marín J, et al. The membrane-spanning 4-domains, subfamily A (MS4A) gene cluster contains a common variant associated with Alzheimer's disease. Genome Med 2011; 3 : 33.
63Lue LF, Schmitz CT, Serrano G, Sue LI, Beach TG, Walker DG, et al. TREM2 protein expression changes correlate with Alzheimer's disease neurodegenerative pathologies in post-mortem temporal cortices. Brain Pathol 2015; 25 : 469-80.
64Bouchon A, Dietrich J, Colonna M. Cutting edge: Inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol 2000; 164 : 4991-5.
65Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, et al. Variant of TREM2 associated with the risk of Alzheimer's disease.N Engl J Med 2013; 368 : 107-16.
66Prinz M. Microglia lineage and development. In: Kettenmann H, Ransom BR, editors. Neuroglia. New York: Oxford University Press; 2013. p. 172-84.
67Melchior B, Garcia AE, Hsiung BK, Lo KM, Doose JM, Thrash JC, et al. Dual induction of TREM2 and tolerance-related transcript, tmem176b, in amyloid transgenic mice: Implications for vaccine-based therapies for Alzheimer's disease. ASN Neuro 2010; 2 : e00037.
68D'Andrea MR, Cole GM, Ard MD. The microglial phagocytic role with specific plaque types in the Alzheimer disease brain. Neurobiol Aging 2004; 25 : 675-83.
69Takahashi K, Rochford CD, Neumann H. Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J Exp Med 2005; 201 : 647-57.
70Xu W, Tan L, Yu JT. The role of PICALM in Alzheimer's disease. Mol Neurobiol 2015; 52 : 399-413.
71Tebar F, Bohlander SK, Sorkin A. Clathrin assembly lymphoid myeloid leukemia (CALM) protein: Localization in endocytic-coated pits, interactions with clathrin, and the impact of overexpression on clathrin-mediated traffic. Mol Biol Cell 1999; 10 : 2687-702.
72Cirrito JR, Kang JE, Lee J, Stewart FR, Verges DK, Silverio LM, et al. Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron 2008; 58 : 42-51.
73Nordstedt C, Caporaso GL, Thyberg J, Gandy SE, Greengard P. Identification of the Alzheimer beta/A4 amyloid precursor protein in clathrin-coated vesicles purified from PC12 cells. J Biol Chem 1993; 268 : 608-12.
74Thinakaran G, Koo EH. Amyloid precursor protein trafficking, processing, and function. J Biol Chem 2008; 283 : 29615-9.
75Ford MG, Pearse BM, Higgins MK, Vallis Y, Owen DJ, Gibson A, et al. Simultaneous binding of ptdIns(4,5)P2 and clathrin by AP180 in the nucleation of clathrin lattices on membranes. Science 2001; 291 : 1051-5.
76Harel A, Wu F, Mattson MP, Morris CM, Yao PJ. Evidence for CALM in directing VAMP2 trafficking. Traffic 2008; 9 : 417-29.
77Sakamuro D, Elliott KJ, Wechsler-Reya R, Prendergast GC. BIN1 is a novel MYC-interacting protein with features of a tumour suppressor. Nat Genet 1996; 14 : 69-77.
78Wu T, Shi Z, Baumgart T. Mutations in BIN1 associated with centronuclear myopathy disrupt membrane remodeling by affecting protein density and oligomerization. PLoS One 2014; 9 : e93060.
79Tan MS, Yu JT, Tan L. Bridging integrator 1 (BIN1): Form, function, and Alzheimer's disease. Trends Mol Med 2013; 19 : 594-603.
80Karch CM, Jeng AT, Nowotny P, Cady J, Cruchaga C, Goate AM, et al. Expression of novel Alzheimer's disease risk genes in control and Alzheimer's disease brains. PLoS One 2012; 7 : e50976.
81Lee JH, Cheng R, Barral S, Reitz C, Medrano M, Lantigua R, et al. Identification of novel loci for Alzheimer disease and replication of CLU, PICALM, and BIN1 in caribbeanhispanic individuals. Arch Neurol 2011; 68 : 320-8.
82Tang VW, Brieher WM. FSGS3/CD2AP is a barbed-end capping protein that stabilizes actin and strengthens adherens junctions. J Cell Biol 2013; 203 : 815-33.
83Dunstan ML, Gerrish A, Morgan T, Owens H, Badarinarayan N, Thomas RS, et al. The role of CD2AP in APP processing. Alzheimers Dement 2016; 12 : P458-9.
84Sannerud R, Annaert W. Bin1 and CD2AP polarize aβ generation in neurons. EMBO Rep 2017; 18 : 5-7.
85Mehta KM, Yaffe K, Pérez-Stable EJ, Stewart A, Barnes D, Kurland BF, et al. Race/ethnic differences in AD survival in US Alzheimer's disease centers. Neurology 2008; 70 : 1163-70.
86Lin YL, Chen SY, Lai LC, Chen JH, Yang SY, Huang YL, et al. Genetic polymorphisms of clusterin gene are associated with a decreased risk of Alzheimer's disease. Eur J Epidemiol 2012; 27 : 73-5.
87Klimkowicz-Mrowiec A, Sado M, Dziubek A, Dziedzic T, Pera J, Szczudlik A, et al. Lack of association of CR1, PICALM and CLU gene polymorphisms with Alzheimer disease in a Polish population. Neurol Neurochir Pol 2013; 47 : 157-60.
88Chung SJ, Lee JH, Kim SY, You S, Kim MJ, Lee JY, et al. Association of GWAS top hits with late-onset Alzheimer disease in Korean population. Alzheimer Dis Assoc Disord 2013; 27 : 250-7.
89Reitz C, Jun G, Naj A, Rajbhandary R, Vardarajan BN, Wang LS, et al. Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E ϵ4, and the risk of late-onset Alzheimer disease in African Americans. JAMA 2013; 309 : 1483-92.
90Bertram L, Tanzi RE. Genetics of Alzheimer's disease. In: Dickson D, Weller R, editors. Neurodegeneration: The molecular pathology of dementia and movement disorders, 2nd ed. West Sussex: Wiley-Blackwell; 2011. p. 51-91.
91Pimplikar SW. Neuroinflammation in Alzheimer's disease: From pathogenesis to a therapeutic target. J Clin Immunol 2014; 34 (Suppl 1) : S64-9.
92Wilson MR, Zoubeidi A. Clusterin as a therapeutic target. Expert Opin Ther Targets 2017; 21 : 201-13.
93Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet 2013; 45 : 1452-8.
94Medway C, Morgan K. The genetics of Alzheimer's disease; putting flesh on the bones. Neuropathol Appl Neurobiol 2014; 40 : 97-105.